LeMaitre Vascular, Inc. (LMAT): Price and Financial Metrics
LeMaitre Vascular, Inc. (LMAT)
Today's Latest Price: $38.88 USD
Updated Nov 23 6:55pm
Add LMAT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
LMAT Stock Summary
- LMAT's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,616.42 -- higher than 97.52% of US-listed equities with positive expected earnings growth.
- The price/operating cash flow metric for Lemaitre Vascular Inc is higher than 85.88% of stocks in our set with a positive cash flow.
- With a year-over-year growth in debt of 1,091.05%, Lemaitre Vascular Inc's debt growth rate surpasses 98.21% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Lemaitre Vascular Inc are SSTK, SSD, ATRI, PLPC, and CRTO.
- LMAT's SEC filings can be seen here. And to visit Lemaitre Vascular Inc's official web site, go to www.lemaitre.com.
LMAT Stock Price Chart Interactive Chart >
LMAT Price/Volume Stats
| Current price | $38.88 | 52-week high | $39.40 |
| Prev. close | $37.75 | 52-week low | $18.76 |
| Day low | $36.86 | Volume | 167,800 |
| Day high | $39.40 | Avg. volume | 131,781 |
| 50-day MA | $33.99 | Dividend yield | 0.98% |
| 200-day MA | $29.07 | Market Cap | 790.90M |
LeMaitre Vascular, Inc. (LMAT) Company Bio
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease. The company was founded in 1983 and is based in Burlington, Massachusetts.
LMAT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $38.88 | $47.7 | 26% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Lemaitre Vascular Inc. To summarize, we found that Lemaitre Vascular Inc ranked in the 52th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 27% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for LMAT, they are:
- The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 22.78% of the free cash flow producing stocks we're observing.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 24% |
| 1% | 25% |
| 2% | 26% |
| 3% | 28% |
| 4% | 29% |
| 5% | 30% |
Want more companies with a valuation profile/forecast similar to that of Lemaitre Vascular Inc? See CBPO, SNY, EGRX, AMED, and ACIU.
Loading social stream, please wait...